Topics

Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease

08:53 EDT 13 Sep 2019 | FinanzNachrichten

Discontinuation of studies based on Data Safety Monitoring Board recommendationTOKYO, Sept 13, 2019 - (JCN Newswire) - Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the...

Original Article: Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease

NEXT ARTICLE

More From BioPortfolio on "Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease"

Quick Search